ArticleCancer research2020
Mass Spectrometry Imaging Enables Discrimination of Renal Oncocytoma from Renal Cell Cancer Subtypes and Normal Kidney Tissues.
Article in Cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 56 citations in OpenAlex.
- Intraoperative Mass Spectrometry in Oncology: Technologies, Clinical Applications, and Challenges.Molecules (Basel, Switzerland) · 2026Review
- Structure-preserving multivariate hypothesis testing for mass spectrometry imaging and single-cell data.Bioinformatics (Oxford, England) · 2026Article
- Spatial metabolomics and multiomics integration for breakthroughs in precision medicine for kidney disease.Nature reviews. Nephrology · 2026Review
- Volatile Organic Metabolites as Potential Biomarkers for Genitourinary Cancers: Review of the Applications and Detection Methods.Metabolites · 2025Review
- Article
- Mass spectrometry imaging for unearthing and validating quality markers in traditional Chinese medicines.Chinese herbal medicines · 2025Review
- Application of spatial-omics to the classification of kidney biopsy samples in transplantation.Nature reviews. Nephrology · 2024Review
- Direct Three-Dimensional Mass Spectrometry Imaging with Laser Ablation Remote Atmospheric Pressure Photoionization/Chemical Ionization.Analytical chemistry · 2024Article
- DESI-MSI-guided exploration of metabolic-phenotypic relationships reveals a correlation between PI 38:3 and proliferating cells in clear cell renal cell carcinoma via single-section co-registration of multimodal imaging.Analytical and bioanalytical chemistry · 2024Article
- Investigation of metabolite alterations in the kidneys of methionine-choline-deficient mouse by mass spectrometry imaging.Analytical and bioanalytical chemistry · 2024Article
- Spatial pharmacology using mass spectrometry imaging.Trends in pharmacological sciences · 2024Review
- Spatially resolved visualization of reprogrammed metabolism in hepatocellular carcinoma by mass spectrometry imaging.Cancer cell international · 2023Article
- Promise of spatially resolved omics for tumor research.Journal of pharmaceutical analysis · 2023Review
- Distinguishing Renal Cell Carcinoma From Normal Kidney Tissue Using Mass Spectrometry Imaging Combined With Machine Learning.JCO precision oncology · 2023Article
- Imaging the metabolic reprograming of fatty acid synthesis pathway enables new diagnostic and therapeutic opportunity for breast cancer.Cancer cell international · 2023Article
- Spatial metabolomics reveals skeletal myofiber subtypes.Science advances · 2023Article
- Metabolic signature ofFrontiers in veterinary science · 2023Article
- Recent Advances and Applications of Ambient Mass Spectrometry Imaging in Cancer Research: An Overview.Mass spectrometry (Tokyo, Japan) · 2023Review
- Emerging Computational Methods in Mass Spectrometry Imaging.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Review
- Mass Spectrometry Imaging Spatial Tissue Analysis toward Personalized Medicine.Life (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Precise diagnosis and subtyping of kidney tumors are imperative to optimize and personalize treatment decision for patients. Patients with the most common benign renal tumor, renal oncocytomas, may be overtreated with surgical resection because of limited preoperative diagnostic methods that can accurately identify the benign condition with certainty. In this study, desorption electrospray ionization (DESI)-mass spectrometry (MS) imaging was applied to study the metabolic and lipid profiles of various types of renal tissues, including normal kidney, renal oncocytoma, and renal cell carcinomas (RCC). A total of 73,992 mass spectra from 71 patient samples were obtained and used to build predictive models using the least absolute shrinkage and selection operator (Lasso). Overall accuracies of 99.47% per pixel and 100% per patient for prediction of the three tissue types were achieved. In particular, renal oncocytoma and chromophobe RCC, which present the most significant morphologic overlap and are sometimes indistinguishable using histology alone, were also investigated and the predictive models built yielded 100% accuracy in discriminating these tumor types. Discrimination of three subtypes of RCC was also achieved on the basis of DESI-MS imaging data. Importantly, several small metabolites and lipids species were identified as characteristic of individual tissue types and chemically characterized using tandem MS and high mass accuracy measurements. Collectively, our study shows that the metabolic data acquired by DESI-MS imaging in conjunction with statistical modeling allows discrimination of renal tumors and thus has the potential to be used in the clinical setting to improve treatment of patients with kidney tumor. SIGNIFICANCE: Metabolic data acquired by mass spectrometry imaging in conjunction with statistical modeling allows discrimination of renal tumors and has the potential to be used in the clinic to improve treatment of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.